Modern Office Building Exterior

Featured image by Cheunghyo/Getty Images

Leveraged Loans

Europe’s leveraged loan borrowers shrink 2028 maturity wall, but challenges loom

A sizeable portion of debt remains from the buyout boom of 2021.

Want to see more? Fill out the form below.

I agree to PitchBook’s privacy policy

The launch in April of a two-part extension of Ethypharm’s term loan, pushing maturities out to December 2030, chips away at Europe’s 2028 loan maturity wall. Refinancing and extension activity has already cleared much of the need for borrowers to come to market, but a sizeable portion of debt remains — particularly among sponsor-backed deals from the QE-fueled buyout boom of 2021.

Close to €60 billion of 2028 loan maturities remain to be addressed, with a similar amount due in 2029. Refinancing and extension issuance over the past year has cut the 2028 wall roughly in half from its 2024 peak, pushing it out to a high in 2031 at €95.4 billion.

“The 2028 wall is not yet a problem, but it will become increasingly important in the second half of this year,” said a banker. Sponsors typically look to address maturities around 18 months ahead of due dates, with liabilities turning current 12 months before redemption.

In its Credit Conditions Report Europe Q2, published in March, S&P said refinancing risks remain manageable in the “near term”, while warning that prolonged geopolitical disruption could complicate borrowers’ plans. The agency highlighted issuers in the telecoms, chemicals and packaging sectors as particularly exposed.

Buyout boom
The focus on 2028 maturities reflects the fact that many stem from deals struck in 2021 at the height of the post-GFC, QE-driven buyout boom. These credits began to come into view last year and were highlighted by analysts, including Craig Nicol and Oleg Melentyev at Sona — who noted in a November paper that this cohort included the largest-ever share of buyouts with leverage of at least 6x, at 45%.

A manager agreed. “The 2028 maturity wall is more significant than previous cycles, largely because it reflects 2021-vintage credits. That is, deals priced in the immediate post-Covid period with low coupons and elevated leverage,” he said.

LCD data suggests sponsors have been slower to address 2021-vintage deals. In the 12 months to March, the overall 2028 maturity wall was reduced by around €50 billion. While roughly €20.7 billion of that related to 2021 issuance, this effort left some €30.9 billion of 2021-vintage maturities still to be refinanced as of April.

Some of this debt should be straightforward to refinance. Among the largest exposures are French consumer health group Cooper and telecoms infrastructure group Circet — both of which are now marked above par in secondary. Roughly 42% of the 2028 maturities in the Morningstar European Leveraged Loan Index (ELLI) are quoted at 99 or higher, according to LCD.

Storied names
Other names are heading towards a restructuring, with roughly 19.5% of the 2028 requirement quoted below 80 in secondary, and a further 14% below 90. At the more distressed end, investors are also increasingly focused on the risk of liability management exercises (LMEs), with loose documentation leaving lenders exposed to aggressive sponsor moves. “Docs are loose and people are really nervous of LME risk,” said one manager, noting that beyond a certain point, trading can become highly technical and leave investors with limited options.

Healthcare is the largest sector within the 2028 loan maturities. It includes credits such as French labs group Cerba, which S&P in April downgraded to CCC- after confirming the opening of two mandats ad hoc ahead of expected restructuring talks with lenders.

The market had meanwhile been confident of a successful outcome for Cerba’s France-based rival Biogroup, after the latter borrower signalled its intention to refinance debt in an April earnings call.

Biogroup duly stepped out with a lender call on April 27 for a refinancing to address secured and unsecured maturities into a TLB and secured bond due August 2031. Proceeds from the deal will refinance its €1.75 billion term loan B due 2028, as well as bonds. The transaction extends the loan by 3.5 years.

A similar divergence is evident outside the healthcare segment. On April 20, Moody’s changed the outlook on France-based property services group Emeria to negative from stable, affirming its Caa1 issuer and secured ratings. Emeria’s debt stems from a €1.925 billion package priced in 2021, and Moody’s noted persistent negative cash flow despite broadly stable EBITDA. The group also has unsecured notes due March 2029, now quoted in the mid-20s. Emeria’s term loans are in the low-80s, up from a low point in the mid-to-high 70s during April’s war-related weakness.

Software test
A broader test could come from the software sector, which makes up the second-largest portion of the 2028 loan maturity wall. “Lenders’ approach to extending software names will demonstrate their willingness to back credits that are performing but still come with questions,” said a lender.

Since February’s initially indiscriminate sell-off on AI risk, investors have taken a more granular approach to the software sector. As a result, some names — such as enterprise software provider Unit4, which has an €875 million term loan due June 2028 — have largely retraced losses and are now quoted around par.

A larger group of credits — including 2028 names such as Cegid and Think-cell — have recovered some, but not all, of their losses. France-based Cegid, for example, was among the tech names to engage with lenders in February to address concerns about its position in the software ecosystem. The group also acquired European fintech Shine in late 2025, and was understood to be speaking to lenders earlier this year about potential financing, though no deal materialised.

Credit quality
The scale of the challenge could, some argue, shift risk appetites — and price requirements. “Deterioration in credit quality looks set to accelerate, with the key question being whether markets reprice risk accordingly,” said a manager. For now, while rating actions have turned more negative, default rates remain low. S&P still expects its European speculative-grade default rate to end 2026 at 3.25%, down from 4% at the end of 2025.

While downgrades accounted for close to 80% of rating actions in early 2026, the negative bias among speculative-grade issuers at the end of February stood at 14.5%, compared with a long-term average of 17.3%, says S&P.

Within the ELLI, around 80% of 2028 maturities are rated single-B (including B-), while around 12% are in the triple-C category.

Challenges ahead
Meanwhile, the effects of the Iran war pose challenges that are not yet fully clear. Since the closure of the Strait of Hormuz, some chemicals names have traded higher due to disruption to low-cost Chinese imports and higher energy costs for Middle Eastern rivals, sources explain.

This dynamic has helped to provide some relief for a sector now in its third year of a cyclical downturn — although a prolonged conflict could weigh on economic growth, reducing volumes while raising input costs. Under a pessimistic scenario, S&P said default rates could rise to about 4.5%. Chemicals borrowers make up the third-largest sector in the 2028 loan maturity wall.

In response, lenders say the overall approach remains pragmatic, while April’s extension of speciality chemicals group Archroma’s $846 million cross-border term loan suggests lenders are open to complex credits.

Archroma’s euro term loan had fallen to around 70 in autumn 2025, and was marked in the mid-to-high 80s ahead of the April 1 launch of the extension. The deal is due to close at the end of April, after an elongated marketing process that was extended to allow a review of documentation changes.

Sign up for The Credit Pitch

Weekly coverage of US and European loans, bonds, private credit, and more.

Featured image by Cheunghyo/Getty Images

Learn about our editorial standards.